DOMH - Dominari Holdings Inc.


3.04
-0.030   -0.987%

Share volume: 40,347
Last Updated: 03-05-2026
Trading/Security And Commodity Brokers, Dealers, Exchanges & Services: 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.07
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
49%
Profitability 43%
Dept financing 21%
Liquidity 63%
Performance 60%
Company vs Stock growth
vs
Performance
5 Days
0.33%
1 Month
-18.50%
3 Months
-20.63%
6 Months
-50.08%
1 Year
-54.56%
2 Year
47.57%
Key data
Stock price
$3.04
P/E Ratio 
1.11
DAY RANGE
$2.97 - $3.09
EPS 
$5.54
52 WEEK RANGE
$2.85 - $8.40
52 WEEK CHANGE
-$50.73
MARKET CAP 
122.113 M
YIELD 
7.62%
SHARES OUTSTANDING 
0.000
DIVIDEND
$0.32
EX-DIVIDEND DATE
02-24-2025
NEXT EARNINGS DATE
04-29-2025
BETA 
2.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$73,018
AVERAGE 30 VOLUME 
$93,075
Company detail
CEO: Anthony C. Hayes
Region: US
Website: aikidopharma.com
Employees: 4
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Trading/Security And Commodity Brokers, Dealers, Exchanges & Services
Sector: Finance, Insurance, And Real Estate

AIkido Pharma Inc. focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses.

Recent news